three years of regulatory threads, summarised so you do not have to read them
The title is the argument: three years of regulatory threads, summarised so you do not have to read them. Here is the rest of it. Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim. Research-use-only material is not…
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Purity by area percent tells you the sample is homogeneous.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
short peptides are cheap, which cuts both ways
Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.
read the actual papers, they are more modest than the summaries
Citation requested rather than removal. A claim here should say whether its source is preclinical.
Has anyone posted an independent result on that batch?
sequence confirmation is the test worth paying for
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.